Amy Bachrodt's departure as Senior Vice President, Finance of Maze Therapeutics, Inc. was reported, effective June 1, 2026; the filing names no successor. As of November 6, 2026, Maze Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 22, 2026 to August 17, 2026, naming 1 appointment and 2 departures (Form 8-K, May 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Maze Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Maze Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-22 to 2026-08-17. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Maze Therapeutics, Inc. files it.
Also on the record for Maze Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Paradigm BioCapital Advisors LP | — | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 5.8% of the class | 5%+ stakes | Source |
| April 1, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 6.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Third Rock Ventures IV, L.P. | 9.3% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by Alphabet Holdings LLC | 2.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by James Tananbaum | 1.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 7.3% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Matrix Capital Management Company, LP | 3.5% of the class | 5%+ stakes | Source |
| October 17, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 9.02% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Maze Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Maze Therapeutics, Inc. and the records around it.
Maze Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- IPO filing Oct 2025
- Who owns it
Companies that share a holder
- Third Rock Ventures IV, L.P. also filed stake reports on 1 other company: Tango Therapeutics, Inc. (Feb 2026)
- Foresite Capital Fund IV, L.P. also filed stake reports on 2 other companies: Lyell Immunopharma, Inc. (Aug 2026), Eikon Therapeutics, Inc. (Feb 2026)
- GV 2019, L.P. also filed stake reports on 2 other companies: Ethos Technologies Inc. (Nov 2026), Prime Medicine, Inc. (Nov 2025)
Watch Maze Therapeutics, Inc.
Get an email when Maze Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Maze Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Maze Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Maze Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-17 | In | Director | 2026-08-13 | 8-K, 2026-08-17 | |
| 2026-08-17 | Out | Director | 2026-08-13 | 8-K, 2026-08-17 | |
| 2026-05-22 | Out | Senior Vice President, Finance | 2026-06-01 | 8-K, 2026-05-22 |
Who leads Maze Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Paula A. Johnson, appointed, effective 2026-08-13 (filed 2026-08-17).
- Senior Vice President, Finance: Amy Bachrodt, departure reported, effective 2026-06-01 (filed 2026-05-22). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Maze Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Maze Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Maze Therapeutics, Inc.Every change, in the filing's words
Appointed: Paula A. Johnson, Director, effective 2026-08-13
On August 13, 2026, the Board of Directors (the "Board") of Maze Therapeutics, Inc. (the "Company") appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the "Appointment Date").
Departing: Herv Hoppenot, Director, effective 2026-08-13
Also effective August 13, 2026, Herv Hoppenot resigned from his position as a Class II director (with a term expiring at the Company's 2027 annual meeting of stockholders), subject to and conditioned upon his immediate reappointment as a Class III director, and the Board accepted Mr. Hoppenot's resignation and immediately reappointed him as a Class III director with a term expiring at the Company's 2028 annual meeting of stockholders.
- Dr. Johnson will serve as a Class III director for a term expiring at the Company's 2028 annual meeting of stockholders, and Dr. Kornowski will serve as a Class I director for a term expiring at the Company's 2029 annual meeting of stockholders, in each case until such director's successor is duly elected and qualified, or until such director's earlier death, resignation, disqualification, retirement or removal.
- The Board appointed Dr. Johnson to serve as a member of the nominating and corporate governance committee of the Board, and appointed Dr. Kornowski to serve as a member of the audit committee and the compensation committee of the Board, in each case effective as of the Appointment Date.
- Dr. Johnson, age 66, has served as the President of Wellesley College since 2016.
- Prior to that, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital, a Harvard teaching hospital, and as Chief of the Division of Women's Health at Brigham and Women's Hospital, in each case from July 2002 to June 2016.
- She also served as the Grayce A. Young Family Professor of Medicine in Women's Health at Harvard Medical School and as a Professor of Epidemiology at the Harvard T.H. Chan School of Public Health.
Departing: Amy Bachrodt, Senior Vice President, Finance, effective 2026-06-01
On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the "Company"), effective June 1, 2026.
- Ms. Bachrodt's resignation was not as a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices or on any matter relating to the Company's financial reporting.
- Misbah Tahir, the Company's Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt's departure.
Tools for this story
Each opens in a new tab, filled in for Maze Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.